Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients
The Kaohsiung Journal of Medical Sciences · 2024
DOI: 10.1002/kjm2.12838 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2024. Verfasst von Hui-Ling Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Chang Gung Memorial Hospital, Chiayi, Taiwan. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In 2008, sorafenib became the first approved systemic therapeutic agent for advanced HCC. Although its pharmacological efficacy has been established, reimbursement for such a new, high‐cost drug, as well as physicians' awareness and prescription practice, likewise contribute to its clinical effectiveness. We therefore conducted a retrospective study using 38 sorafenib‐eligible, advanced HCC patients when sorafenib was approved but not yet reimbursed as a control and 216 patients during the reimbursed era. Study group showed longer survival at 8.2 months versus the control's 4.9 months ( p = 0.0063 hazard ratio: 0.612 [0.431 ~ 0.868], p = 0.0059). Among the 42 (19.4%) patients who survived more than 2 years, 50% had tumor rupture, and all 32 patients with portal vein tumor thrombus and/or extrahepatic metastasis received sorafenib ( p = 0.003). Furthermore, during their first 2 years of HCC management, sorafenib had been given in 29.1% of the treatment courses among survivors between 2 and 5 years while it was prescribed in 55.8% among the more than 5 years survivor group ( p < 0.001). In conclusion, survival of sorafenib‐eligible HCC patients significantly improved after reimbursement. Patients who underwent longer sorafenib treatment had a survival advantage, except for those with tumor rupture. Reimbursement and awareness of prescriptions for a newly introduced medication therefore improve clinical effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Chang Gung Memorial Hospital, Chiayi, Taiwan.
- Department of Management Information Systems, National Chung Cheng University Chiayi, Chiayi, Taiwan.
- Department of Hepatology and Gastroenterology, Division of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Section of Gastroenterology, Department of Internal Medicine, De Los Santos Medical Center, Quezon City, Philippines.
- Department of Hepato-Gastroenterology, Division of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Hui-Ling Huang, Sheng-Nan Lu
Zitieren
APA
Huang, H. L., Chang, T. S., Canseco, L. M., Wu, F., & Lu, S. N. (2024). Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12838
Vancouver
Huang HL, Chang TS, Canseco LM, Wu F, Lu SN. Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences. 2024. doi:10.1002/kjm2.12838
BibTeX
@article{Huang2024,
author = {Huang, Hui-Ling and Chang, Te-Sheng and Canseco, Lariza Marie and Wu, Fan and Lu, Sheng-Nan},
title = {Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2024},
doi = {10.1002/kjm2.12838}
}
EUVIMED